These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

263 related articles for article (PubMed ID: 19494061)

  • 1. Cephalosporin MIC distribution of extended-spectrum-{beta}-lactamase- and pAmpC-producing Escherichia coli and Klebsiella species.
    Kohner PC; Robberts FJ; Cockerill FR; Patel R
    J Clin Microbiol; 2009 Aug; 47(8):2419-25. PubMed ID: 19494061
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Plasmid-Mediated AmpC β-Lactamase and Underestimation of Extended-Spectrum β-Lactamase in Cefepime-Susceptible Elevated-Ceftazidime-MIC Enterobacteriaceae Isolates.
    Nishimura F; Morinaga Y; Akamatsu N; Matsuda J; Kaku N; Takeda K; Uno N; Kosai K; Hasegawa H; Yanagihara K
    Jpn J Infect Dis; 2018 Jul; 71(4):281-285. PubMed ID: 29709981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Evaluation of the NCCLS extended-spectrum beta-lactamase confirmation methods for Escherichia coli with isolates collected during Project ICARE.
    Tenover FC; Raney PM; Williams PP; Rasheed JK; Biddle JW; Oliver A; Fridkin SK; Jevitt L; McGowan JE;
    J Clin Microbiol; 2003 Jul; 41(7):3142-6. PubMed ID: 12843054
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Can results obtained with commercially available MicroScan microdilution panels serve as an indicator of beta-lactamase production among escherichia coli and Klebsiella isolates with hidden resistance to expanded-spectrum cephalosporins and aztreonam?
    Moland ES; Sanders CC; Thomson KS
    J Clin Microbiol; 1998 Sep; 36(9):2575-9. PubMed ID: 9705395
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the Clinical and Laboratory Standards Institute phenotypic confirmatory test to detect the presence of extended-spectrum β-lactamases from 4005 Escherichia coli, Klebsiella oxytoca, Klebsiella pneumoniae and Proteus mirabilis isolates.
    Morrissey I; Bouchillon SK; Hackel M; Biedenbach DJ; Hawser S; Hoban D; Badal RE
    J Med Microbiol; 2014 Apr; 63(Pt 4):556-561. PubMed ID: 24478449
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluation of MicroScan WalkAway and Vitek 2 for determination of the susceptibility of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae isolates to cefepime, cefotaxime and ceftazidime.
    Jang W; Park YJ; Park KG; Yu J
    J Antimicrob Chemother; 2013 Oct; 68(10):2282-5. PubMed ID: 23671215
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Unreliable extended-spectrum beta-lactamase detection in the presence of plasmid-mediated AmpC in Escherichia coli clinical isolates.
    Robberts FJ; Kohner PC; Patel R
    J Clin Microbiol; 2009 Feb; 47(2):358-61. PubMed ID: 19109470
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Faecal colonization of E. coli and Klebsiella spp. producing extended-spectrum beta-lactamases and plasmid-mediated AmpC in Mozambican university students.
    Chirindze LM; Zimba TF; Sekyere JO; Govinden U; Chenia HY; Sundsfjord A; Essack SY; Simonsen GS
    BMC Infect Dis; 2018 May; 18(1):244. PubMed ID: 29843632
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Susceptibility patterns to extended-spectrum cephalosporins among Enterobacteriaceae harbouring extended-spectrum β-lactamases using the updated Clinical and Laboratory Standards Institute interpretive criteria.
    Kristo I; Pitiriga V; Poulou A; Zarkotou O; Kimouli M; Pournaras S; Tsakris A
    Int J Antimicrob Agents; 2013 Apr; 41(4):383-7. PubMed ID: 23375981
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Relationship between the distribution of cefepime minimum inhibitory concentrations and detection of extended-spectrum β-lactamase production among clinically important Enterobacteriaceae isolates obtained from patients in intensive care units in Taiwan: results from the Surveillance of Multicenter Antimicrobial Resistance in Taiwan (SMART) in 2007.
    Jean SS; Lee WS; Bai KJ; Lam C; Hsu CW; Yu KW; Liao CH; Chang FY; Ko WC; Wu JJ; Chen YH; Chen YS; Liu JW; Lu MC; Liu CY; Chen RJ; Hsueh PR
    J Microbiol Immunol Infect; 2015 Feb; 48(1):85-91. PubMed ID: 23973410
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Susceptibility of extended-spectrum-beta-lactamase-producing Enterobacteriaceae according to the new CLSI breakpoints.
    Wang P; Hu F; Xiong Z; Ye X; Zhu D; Wang YF; Wang M
    J Clin Microbiol; 2011 Sep; 49(9):3127-31. PubMed ID: 21752977
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Use of the cefepime-clavulanate ESBL Etest for detection of extended-spectrum beta-lactamases in AmpC co-producing bacteria.
    Mohanty S; Gaind R; Ranjan R; Deb M
    J Infect Dev Ctries; 2009 Nov; 4(1):24-9. PubMed ID: 20130375
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The molecular characteristics of cefepime-susceptible Escherichia coli and Klebsiella spp. isolates with a positive β-lactamase screening test result but negative confirmation.
    Hu F; Wu W; Ye X; Xu X; Zhu D
    Eur J Clin Microbiol Infect Dis; 2010 Oct; 29(10):1297-9. PubMed ID: 20549530
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Comparison of screening methods for detection of extended-spectrum beta-lactamases and their prevalence among blood isolates of Escherichia coli and Klebsiella spp. in a Belgian teaching hospital.
    Vercauteren E; Descheemaeker P; Ieven M; Sanders CC; Goossens H
    J Clin Microbiol; 1997 Sep; 35(9):2191-7. PubMed ID: 9276386
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Laboratory identification, risk factors, and clinical outcomes of patients with bacteremia due to Escherichia coli and Klebsiella pneumoniae producing extended-spectrum and AmpC type β-lactamases.
    Tsui K; Wong SS; Lin LC; Tsai CR; Chen LC; Huang CH
    J Microbiol Immunol Infect; 2012 Jun; 45(3):193-9. PubMed ID: 22580086
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of plasmid-mediated AmpC beta-lactamases in Escherichia coli, Klebsiella spp., and proteus species can potentially improve reporting of cephalosporin susceptibility testing results.
    Tenover FC; Emery SL; Spiegel CA; Bradford PA; Eells S; Endimiani A; Bonomo RA; McGowan JE
    J Clin Microbiol; 2009 Feb; 47(2):294-9. PubMed ID: 19036936
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Cefotaxime for the detection of extended-spectrum β-lactamase or plasmid-mediated AmpC β-lactamase and clinical characteristics of cefotaxime-non-susceptible Escherichia coli and Klebsiella pneumoniae bacteraemia.
    Matsumura Y; Yamamoto M; Matsushima A; Nagao M; Ito Y; Takakura S; Ichiyama S
    Eur J Clin Microbiol Infect Dis; 2012 Aug; 31(8):1931-9. PubMed ID: 22210267
    [TBL] [Abstract][Full Text] [Related]  

  • 18. In vitro activity of flomoxef and comparators against Escherichia coli, Klebsiella pneumoniae and Proteus mirabilis producing extended-spectrum β-lactamases in China.
    Yang Q; Zhang H; Cheng J; Xu Z; Xu Y; Cao B; Kong H; Ni Y; Yu Y; Sun Z; Hu B; Huang W; Wang Y; Wu A; Feng X; Liao K; Shen D; Hu Z; Chu Y; Lu J; Su J; Gui B; Duan Q; Zhang S; Shao H
    Int J Antimicrob Agents; 2015 May; 45(5):485-90. PubMed ID: 25600890
    [TBL] [Abstract][Full Text] [Related]  

  • 19. In vitro activities and detection performances of cefmetazole and flomoxef for extended-spectrum β-lactamase and plasmid-mediated AmpC β-lactamase-producing Enterobacteriaceae.
    Matsumura Y; Yamamoto M; Nagao M; Tanaka M; Takakura S; Ichiyama S
    Diagn Microbiol Infect Dis; 2016 Apr; 84(4):322-7. PubMed ID: 26782634
    [TBL] [Abstract][Full Text] [Related]  

  • 20. A nationwide study of mechanisms conferring reduced susceptibility to extended-spectrum cephalosporins in clinical Escherichia coli and Klebsiella spp. isolates.
    Tofteland S; Dahl KH; Aasnæs B; Sundsfjord A; Naseer U
    Scand J Infect Dis; 2012 Dec; 44(12):927-33. PubMed ID: 22991975
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.